SCHEMBL4147000

SCHEMBL4147000

CNC(=O)c1ccc(N2CCC3(CCN(Cc4ccccc4)CC3)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.56
CHRM2 P08172 2/20 0.55
CHRM3 P20309 2/20 0.55
HDAC4 P56524 2/20 0.55
HDAC1 Q13547 2/20 0.55
HDAC3 O15379 1/20 0.55
HDAC7 Q8WUI4 1/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
HDAC9 Q9UKV0 1/20 0.55
HDAC5 Q9UQL6 1/20 0.55
MAPT P10636 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
TSHR P16473 2/20 0.53
KCNH2 Q12809 2/20 0.52
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4130762 0.84 ITGB3 (0.49) HDAC3HDAC8HDAC6KCNH2CYP3A4
SCHEMBL9407904 0.77 HDAC4 (0.72) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL12341280 0.77 HDAC1 (0.81) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL4140495 0.77 USP2 (0.55) CYP2D6HDAC3HDAC8HDAC6TSHR
SCHEMBL4142700 0.76 ALDH1A1 (0.44) CYP2D6HDAC3HDAC8HDAC6MAPT
SCHEMBL4125514 0.75 HRH3 (0.51) CYP2D6HDAC1HDAC8HDAC6L3MBTL1
SCHEMBL7947565 0.74 PARP1 (0.54) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL1482123 0.74 HTR2A (0.69) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL1066467 0.74 HTR2A (0.72) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL4653292 0.74 MAPT (0.66) HDAC4HDAC1HDAC3HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 CYP2D6 1049/4885CHRM2 78/4885CHRM3 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.